Fix the following errors:
precisionlife gives us a powerful new way to study and understand complex diseases. It finds unique disease signatures that lead us quickly to the right targets in the right tissues and the right patients, and helps us understand how best to tackle disease.
+44 (0) 1865 575 170
Office hours 9am - 6pm
AI Enabled Drug Discovery
precisionlife’s drug discovery platform brings together a patented mathematical framework, AI and deep semantic algorithms to mine existing research data. We use these insights to generate new mechanistic explanations of the interactions between genes, metabolic pathways, diseases and drugs.
Dr Steve Gardner
Chief Executive Officer
UK
C9 Glyme Court, Langford Lane
Kidlington, OX5 1LQ
USA
1 Broadway
Cambridge 02142, MA
DENMARK
Agern Allé 3
DK-2970 Hørsholm
POLAND
26 Zurawia St. Loc 10
00-515 Warsaw
Copyright 2018 RowAnalytics Ltd | Read our Privacy Policy | All Rights Reserved
+44 (0) 1865 575 170
Office hours 9am - 6pm
Steve is a pioneer of healthcare informatics with over 25 years' experience.
He specialises in developing and commercializing novel data science and informatics applications in multiple companies in the US, UK & mainland Europe. He is a former Global Director of Research Informatics for Astra A/B and an Advisory Council member for Breast Cancer Now and UKCRC. He has published over 30 papers and is principal inventor on 24 patents & applications.
Previous events:
Intersections – 20th November 2018
View Event
TIPLO AI Dinner – 9th October 2018
View Event
GEC+ Taipei – 26th-29th September 2018
View Event
MedCity Converge – 11th-12th July 2018
View Event
precisionlife is a radical new approach to complex disease analysis.
Dr Steve Gardner
Chief Executive Officer
• Multiple novel validated drug targets from existing datasets
• Targeted drug repurposing opportunities
• Improved biomarker-driven patient stratification strategies
precisionlife is delivering:
Complex diseases such as oncology, neurodegenerative, psychiatry and cardiometabolic disease don't have simple, single gene explanations. If we want to understand why some patients have higher risk or respond to drugs differently, we need to look deeper.
precisionlife has a unique ability to rapidly find all of the combinations of genomic, phenotypic and clinical features that define disease risk, prognosis and therapy response in a complex disease population. We have proven that these disease signatures can lead us to validated targets, drug discovery opportunities and better personalized medicine.
Meet the precisionlife team at these events:
AI Enabled Precision Medicine
Our deeper insights into the structure of disease populations give us a better quantitative understanding the clinical significance of the combination of an individual patient's features. That empowers truly personal precision medicine.
• Precision medicine clinical decision support tools
• More precise personalized risk scoring
• Fully personalized digital health solutions
precisionlife is delivering:
Dr Véronique Bouchet, MBA
Chief Medical Officer
She specialises in bridging the gap from research to commercialisation. She is a former Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca, where she was responsible for AZ’s global corporate venturing activities, including the creation and $40M financing of the company’s first GI spinout, Albireo.
Véronique has over 30 years’ international experience in healthcare.
Contact us to find out more about partnering and licensing opportunities for the precisionlife platform.
+44 (0) 1865 575 170
Office hours 9am - 6pm
precisionlife is proud to hold ISO27001:2013 accreditation.
Our partners and users can be confident in our information security processes.
precisionlife is proud to hold ISO27001:2013 accreditation. Our partners and users can be confident in our information security processes.
BioData World, Basel – 28th-29th November 2018
Harnessing the Power of Big Data in Precision Medicine
London IP Week Panel Discussion, London – 11th December 2018
Artificial Intelligence (A.I.): Benevolent Innovator or Patent Destroyer?
Genesis, London – 13th December 2018
Convergence of Academia and Business: Commercialising Multi-Disciplinary Research